IMMUNE CHECKPOINT INHIBITORS (ICIS)
Clinical trials for IMMUNE CHECKPOINT INHIBITORS (ICIS) explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITORS (ICIS) trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS (ICIS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer: smart combo targets hidden risk after immunotherapy
Disease control Recruiting nowThis study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who did well on initial immunotherapy but still have signs of cancer DNA in their blood. About 70 adults aged 18-75 will be randomly assigned…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS (ICIS)
Phase: PHASE2 • Sponsor: Second Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can we predict dangerous blood clots in lung cancer immunotherapy patients?
Knowledge-focused Recruiting nowThis study looks at how often lung cancer patients on immune checkpoint inhibitors develop blood clots (in veins or arteries) and what factors increase that risk. Researchers will follow 2,400 adults with lung cancer who are starting immunotherapy, comparing those who get clots w…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS (ICIS)
Sponsor: Beijing Chao Yang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC